Your session is about to expire
← Back to Search
PET Radiotracer Imaging for Neuroendocrine Cancer
Phase < 1
Recruiting
Led By David Raffel, Ph.D.
Research Sponsored by University of Michigan Rogel Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Able to lie flat for 60 minutes
Current neuroendocrine tumor diagnosis
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 90 minutes and 180 minutes after administration of tracer
Awards & highlights
Study Summary
This trial is testing a new method to map and stage neuroendocrine tumors. If successful, this could help doctors treat these tumors more effectively in the future.
Who is the study for?
This trial is for individuals with neuroendocrine tumors who can lie flat for an hour and give informed consent. It's not suitable for those on certain medications like tricyclic antidepressants, cocaine, some blood pressure drugs, nasal decongestants, cold medicines with sympathomimetic amines, tetrabenazine or MAOIs; nor pregnant or breastfeeding women or people with claustrophobia.Check my eligibility
What is being tested?
The study tests if [18F]3F-PHPG PET scans are effective in locating neuroendocrine tumors compared to existing imaging methods like SPECT/CT scans and planar scintigraphy. The aim is to potentially establish [18F]3F-PHPG as a standard tool for tumor localization and staging.See study design
What are the potential side effects?
While the document doesn't list specific side effects of [18F]3F-PHPG, generally PET scan tracers may cause allergic reactions or discomfort at the injection site. Imaging procedures involve lying still which might be uncomfortable.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I can lie flat for an hour without discomfort.
Select...
I have been diagnosed with a neuroendocrine tumor.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 90 minutes and 180 minutes after administration of tracer
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~90 minutes and 180 minutes after administration of tracer
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Biodistribution of [18F]3F-PHPG
Image quality assessed by standardized uptake values
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: PET/CT scan with radiotracer [18F]3F-PHPGExperimental Treatment2 Interventions
Novel radiotracer [18F]3F-PHPG prior to whole-body PET/CT scan.
Group II: Planar scintigraphy/SPECT scans with radiotracer [123I]MIBGActive Control5 Interventions
FDA approved radiotracer [123I]MIBG prior to whole-body planar scintigraphy and SPECT/CT scan (standard clinical imaging procedures).
Find a Location
Who is running the clinical trial?
University of Michigan Rogel Cancer CenterLead Sponsor
293 Previous Clinical Trials
24,067 Total Patients Enrolled
2 Trials studying Neuroendocrine Tumors
116 Patients Enrolled for Neuroendocrine Tumors
David Raffel, Ph.D.Principal InvestigatorUniversity of Michigan Rogel Cancer Center
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am taking Xenazine for my condition.I am not taking cold medicines with phenylephrine, phenylpropanolamine, or pseudoephedrine.I can lie flat for an hour without discomfort.I am not taking any MAOI medications.You are pregnant or breastfeeding.You are afraid of being in small or enclosed spaces.I cannot lie flat for an hour.I am not on medications that affect PET scans for neuroendocrine tumors.I am not taking desipramine, amitriptyline, or imipramine.I do not use cocaine.I am not taking reserpine, labetalol, α-methyldopa, or clonidine for high blood pressure.I have been diagnosed with a neuroendocrine tumor.I am currently using nasal decongestants.
Research Study Groups:
This trial has the following groups:- Group 1: Planar scintigraphy/SPECT scans with radiotracer [123I]MIBG
- Group 2: PET/CT scan with radiotracer [18F]3F-PHPG
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What medical purposes is the Positron emission tomography/computed tomography scan typically employed for?
"Positron emission tomography/computed tomography scan is a widely used treatment for paraganglioma, as well as neoplasm metastasis, primary neuroblastomas, and unresectable iobenguane-scan positive pheochromocytomas."
Answered by AI
How many participants are being taken into this research initiative?
"Affirmative, the clinicaltrials.gov website indicates that this trial is actively enrolling participants. The initial post was published on October 19th 2020 and recently updated on November 8th 2022. This experiment requires 30 individuals from a single centre to complete it."
Answered by AI
Are there any vacancies for individuals wishing to participate in this trial?
"The clinical trial is still open and accepting participants, as per the information found on clinicaltrials.gov. The trial was first posted in October 2020 with its most recent update taking place 11 months later."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger